Replies to post #1326 on Q BioMed Inc (QBIO)

[koen2]

i'm not concerned here

I think it's not smart to short a low float ,low marketcap stock.
Qbio is about to execute there commercialization of there metastron and generic version into the market again.

The two combined had a revenue stream of over 500 million a year with former owners.

So even if we do 25% of that in the first year we are fine .
Also there is a lot of interest from big pharma in the mannin division in Germany